For years, China was known primarily as a manufacturer of generic medicines and active pharmaceutical ingredients (APIs). Today, a new generation of Chinese biopharmaceutical companies is moving into one of the pharmaceutical industry’s most demanding markets: biosimilars.
Their ambitions extend far beyond China. Companies are securing approvals in Europe, the United States, Canada, and emerging markets, signaling that Chinese biotech firms are becoming serious global competitors rather than regional players.
A Rapidly Maturing Industry
China’s biosimilar industry has grown remarkably since regulatory reforms began in 2017. Companies including Henlius, Bio-Thera Solutions, Innovent Biologics, Qilu, and Boan Biotech have invested heavily in developing biosimilars for blockbuster biological drugs used to treat cancer, autoimmune diseases, and other chronic conditions.
Unlike conventional generic drugs, biosimilars are highly complex biological medicines that require sophisticated manufacturing processes, extensive analytical testing, and rigorous regulatory review. Developing them demands years of investment and significant scientific expertise.
The progress Chinese companies have made suggests that the country’s pharmaceutical industry has moved well beyond low-cost manufacturing.
International Approvals Build Credibility
One of the strongest indicators of China’s growing capabilities is regulatory success overseas.
Henlius’ trastuzumab biosimilar has received approvals in Europe, Canada, and the United States through international partners. Bio-Thera has also achieved approvals for biosimilars of bevacizumab and tocilizumab in both Europe and the US, while Innovent has expanded into Southeast Asia.
Winning approval from regulators such as the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) requires manufacturers to demonstrate that their biosimilars match the reference products in quality, safety, and efficacy.
These approvals provide credibility that extends well beyond individual products.
Partnerships Are Driving Global Expansion
Few Chinese companies are expanding entirely on their own.
Instead, many have chosen to partner with established international pharmaceutical companies that already possess commercial infrastructure, regulatory expertise, and established distribution networks.
This strategy allows Chinese developers to focus on research and manufacturing while leveraging global partners for marketing and commercialization.
It also reduces risk and accelerates entry into highly regulated markets.
Lower Costs, Greater Access
The global biosimilars market is expected to grow rapidly as patents expire on many high-value biologic medicines.
Biosimilars typically enter the market at lower prices than the original products, increasing competition and expanding patient access to treatments that were previously too expensive for many healthcare systems.
Chinese manufacturers are positioning themselves to become important suppliers during this transition.
For healthcare providers and patients, greater competition could translate into lower treatment costs and broader access to life-saving medicines.
Challenges Remain
Despite impressive progress, international expansion is far from straightforward.
Competition within China has become increasingly intense, with numerous companies pursuing biosimilars for the same blockbuster medicines. This has created pricing pressure and duplicated development efforts.
International markets also impose demanding regulatory requirements. Products often require additional studies, manufacturing adjustments, and extensive documentation before they can receive approval abroad.
In addition, biosimilars continue to face varying regulatory standards across different countries, making global commercialization more complex than for traditional generic medicines.
Quality Will Determine Long-Term Success
Success in biosimilars is ultimately determined by trust.
Physicians, hospitals, regulators, and patients must be confident that biosimilars deliver the same clinical outcomes as the original biological medicines.
Chinese manufacturers have made significant progress in demonstrating that capability, but maintaining consistent quality across global markets will remain essential if they hope to compete with established international companies.
The Bigger Picture
China’s biosimilars industry illustrates the broader transformation of the country’s pharmaceutical sector.
Rather than competing solely on manufacturing costs, Chinese companies are increasingly investing in advanced biologics, regulatory science, and international partnerships.
The result is a pharmaceutical industry that is becoming more innovative, more global, and more competitive.
As patents continue to expire on many of the world’s highest-selling biologic medicines, Chinese biosimilar developers are well positioned to become important players in global healthcare. The next decade may see them competing not only on price, but also on quality, innovation, and international reach.
Can you afford not to enter the Chinese market? Talk to us, we’ll help you succeed in China.